Every Active Mass Tort at a Glance (2026)

This is the master map. Each row shows whether the litigation is still accepting new plaintiffs, where settlement talks stand, and a link to the detailed guide for that tort. Case counts and dates move every month — this snapshot reflects publicly reported figures as of August 2026. A “settlement framework” or jury verdict does not guarantee you a payment.

The detail behind every row is below. If you only read one more section, read the 3-part qualification test.

Quick Answers to the Top Questions

How do I know if I qualify?

Three things almost always have to line up: documented use or exposure to the product, a diagnosis of a covered injury, and filing before your state’s deadline. The full framework is in the 3-part test below.

Which ones are still open?

Most active torts are still accepting plaintiffs — talc, hair relaxer, Depo-Provera, AFFF, Bard PowerPort, Suboxone, Ozempic, Zantac, Taxotere, Uber, Roblox, social media, NEC, Roundup, and Paraquat among them. The clearest exception is Camp Lejeune, whose window has closed.

Is this a class action?

Usually no. Most are MDLs, where each person keeps an individual case and an individual payout. The big exception in 2026 is Roundup, which is being resolved through a proposed class settlement — though a June 2026 Supreme Court ruling has complicated that picture. See how the two differ.

How much is the payout?

Be skeptical of any site quoting an exact “average.” Real, documented settlement numbers now exist for talc, Paraquat, Zantac, and a handful of others. Everywhere else, no settlement means no real per-person figure. See how much settlements actually are.

Does it cost anything?

Mass tort cases are almost always handled on contingency — no money up front, and the lawyer is paid a percentage only if you recover. See timeline and cost.

What Is a Mass Tort? (and How It Differs From a Class Action)

A mass tort is a large group of personal-injury lawsuits brought over the same product, drug, device, or platform. In federal court, the Judicial Panel on Multidistrict Litigation (the JPML) usually consolidates those cases into a single multidistrict litigation, or MDL, before one judge. The MDL coordinates the shared work — discovery, expert fights, and a handful of test trials — so the same evidence does not have to be re-litigated thousands of times.

The critical point: an MDL is not a class action. In a class action, one outcome is shared by everyone in the class, and any money is divided among them. In an MDL, you keep your own lawsuit. Your settlement or verdict reflects your exposure, your injury, and your damages — not an equal slice of a common pot. That distinction is why the same litigation can produce a $5,000 verdict in one case and a multimillion-dollar verdict in another.

Two practical wrinkles. First, the same product can spawn more than one MDL — Ozempic, for example, has a gastrointestinal-injury MDL (3094) and a separate vision-loss MDL (3163). Second, the same injuries are often litigated in state court in parallel, sometimes moving faster than the federal MDL — Zantac is the clearest current example, where the federal MDL wound down but state-court cases in Delaware, Illinois, and California are still very much alive. And occasionally a defendant resolves a mass tort through a class settlement instead of MDL-by-MDL payouts — which is exactly what is being attempted with Roundup in 2026. To learn how a true class action is built, see how to file a class action lawsuit.

Do You Qualify? The 3-Part Test

Eligibility varies by tort and by state, but nearly every mass tort claim turns on the same three questions. If you can answer yes to all three, it is worth a free case review.

1. Use or exposure. Did you actually use the product, take the drug, receive the device, or get exposed during the relevant window? You generally need to be able to show it — a prescription record, a device implant card, an employment or service record, a purchase history, or platform-account records.
2. A covered diagnosis. Were you diagnosed with one of the specific injuries that the litigation covers? This is where many claims fall apart. Each MDL is built around particular injuries (for example, talc covers ovarian cancer and mesothelioma; Depo-Provera covers meningioma; AFFF focuses on kidney and testicular cancer). A different diagnosis usually will not qualify, even if you used the product.
3. Timeliness. Are you still within your state’s statute of limitations? Deadlines vary widely — often two to four years — and many states use a “discovery rule” that starts the clock when you knew, or reasonably should have known, that your injury was linked to the product. Some windows are closing in 2026, and at least one (Camp Lejeune) has already shut.

What to gather: proof of use or exposure (records, packaging, receipts, implant cards, service/employment history), medical records confirming the diagnosis and its date, and any documentation tying the two together. Strong, complete records are the single biggest factor in whether a claim moves forward.

Mass Torts Still Accepting Plaintiffs (2026)

Grouped by type. Each entry below is a short, current status with a link to the deep-dive guide. None of these has a global settlement that guarantees a payout unless noted.

Drug & medical-device torts

Depo-Provera (MDL 3140). Women who used the Depo-Provera contraceptive injection long-term and later developed a meningioma (a brain or spinal tumor) allege Pfizer failed to warn them. This is one of the fastest-growing pharmaceutical MDLs in the country — roughly 5,500 federal cases, with more in state court. The FDA added a meningioma warning to the U.S. label in December 2025. A pivotal science (Daubert) hearing was held June 24–26, 2026, and the first bellwether trial is scheduled for December 7, 2026. No settlement yet. Read the Depo-Provera guide.

Ozempic and other GLP-1 drugs (MDL 3094 and MDL 3163). Two separate dockets, both before Judge Marston in Pennsylvania. MDL 3094 covers severe gastrointestinal injuries — gastroparesis (“stomach paralysis”), ileus, and bowel obstruction — with roughly 3,700 cases. A newer MDL 3163, created in December 2025, covers NAION, a sudden, often permanent vision loss sometimes called an “eye stroke.” Claims extend to Wegovy and Rybelsus, and to manufacturers Novo Nordisk and Eli Lilly. One wrinkle worth knowing: the FDA has separately warned about compounded semaglutide — copycat versions made by compounding pharmacies rather than the brand manufacturers. If you were injured by a compounded version rather than brand-name Ozempic or Wegovy, you likely face a different legal path and may not qualify for the branded-drug MDL at all. Early stage overall, no settlement. Read the Ozempic guide.

Bard PowerPort (MDL 3081). Patients implanted with the Bard PowerPort catheter — often cancer patients using it for chemotherapy — allege the device’s tubing fractures or migrates, causing infection, blood clots, and emergency surgery. About 3,400 cases sit before Judge Campbell in Arizona. The first bellwether trial ended in a defense verdict in early May 2026, though the jury could not agree on whether the device itself was defective; plaintiffs sought a new trial, and more bellwethers are scheduled. Still accepting claims.

Suboxone (MDL 3092). The sublingual film used to treat opioid-use disorder is acidic, and plaintiffs say long-term use caused severe tooth decay, erosion, and tooth loss that Indivior failed to warn about for years (the FDA added a dental warning in 2022). The case is in Ohio before Judge Calabrese. Deadlines are the live issue here: in states with a two-year limit, the clock that started with the 2022 label change has already run for some claimants, and the court has been dismissing non-compliant cases aggressively. If you think you have a Suboxone claim, do not wait. Trials are not expected until roughly 2028.

Zantac / ranitidine (MDL 2924). Plaintiffs allege the heartburn drug’s active ingredient, ranitidine, breaks down into NDMA, a probable human carcinogen, causing bladder, stomach, and other cancers. The federal MDL in Florida effectively wound down after 2022 rulings excluded plaintiffs’ experts, but that did not end the litigation — it moved to state courts. GlaxoSmithKline settled roughly 80,000 claims for up to $2.2 billion, and Sanofi separately settled about 4,000 more. Cases against Boehringer Ingelheim and Pfizer remain active, with trials ongoing in Illinois and over 70,000 claims still pending in Delaware. Whether you can still file depends heavily on your state’s statute of limitations and which company’s product you used.

Taxotere. Patients allege this chemotherapy drug caused permanent hair loss (alopecia) that Sanofi and other manufacturers failed to adequately warn about. Litigation remains active, with individual case resolutions continuing rather than one global settlement.

Hernia mesh (MDL 2846, MDL 3029 & MDL 2753). Surgical mesh made from synthetic materials such as polypropylene can contract, migrate, or break once implanted, causing chronic pain, infection, adhesions, and bowel obstruction. Most active claims require proof that you underwent a second, revision surgery to repair or remove the mesh. This is really three separate dockets:

• C.R. Bard / Davol (MDL 2846). Centralized in the U.S. District Court for the Southern District of Ohio before Judge Edmund A. Sargus, Jr. This is the largest hernia-mesh docket and covers models such as Ventralex, 3DMax, PerFix Plug, and Ventralight ST. Bard reached a roughly $1 billion settlement framework in 2024, and individual claims continue to be processed under it.
• Covidien / Medtronic (MDL 3029). Centralized in the U.S. District Court for the District of Massachusetts before Judge Patti B. Saris, covering products including Parietex and ProGrip mesh. No global settlement yet.
• Atrium Medical C-QUR (MDL 2753). Pending in the U.S. District Court for the District of New Hampshire before Chief Judge Landya B. McCafferty. No global settlement yet.

Eligibility depends heavily on which manufacturer’s product you had implanted. See product liability claims.

Proton-pump inhibitors / PPI (MDL 2789). People who took heartburn medications including Nexium, Prilosec, Prevacid, Protonix, and Dexilant allege the manufacturers failed to warn that long-term use raises the risk of kidney injury (including acute interstitial nephritis and chronic kidney disease) and, in some cases, gastric cancer. The litigation is consolidated in the U.S. District Court for the District of New Jersey before Judge Claire C. Cecchi. This is an older docket — filed in 2017 — and several major defendants have already settled: AstraZeneca paid $425 million in 2024 to resolve Nexium and Prilosec claims, and Takeda separately reached an agreement in principle the same year. Even so, more than 11,000 cases remained pending as of early 2026, so claims against remaining defendants are still being evaluated. If you took a PPI long-term and were later diagnosed with kidney disease, it is worth a free case review even though this tort gets less attention than newer ones.

Paragard IUD (MDL 2974). Plaintiffs allege the Paragard intrauterine device can break apart during removal, leaving fragments that require surgery. Note the docket number — 2974, not to be confused with the Paraquat MDL (3004). Still active; results so far are mixed.

Consumer-product & chemical torts

Talcum powder (MDL 2738). With roughly 69,000 pending cases, this was the largest active MDL in the federal system — and it just took its biggest step toward resolution. On July 28, 2026, Johnson & Johnson agreed to pay $5.5 billion to settle approximately 76,000 ovarian-cancer claims in federal and state court. The deal is conditioned on at least 95% of remaining claimants agreeing to participate; J&J will make an initial payment of up to $3 billion in 2027, with no further payments due until 2028. This follows three failed attempts to resolve the litigation through a subsidiary’s bankruptcy (the “Texas Two-Step”), the last of which a Houston federal judge dismissed in March 2026. The deal is not yet final. Read the talcum powder guide.

Hair relaxer (MDL 3060). Roughly 11,000-plus women allege that chemical hair straighteners — products marketed for decades disproportionately to Black and Latina women — contain endocrine-disrupting chemicals that caused uterine, endometrial, or ovarian cancer. The Chicago judge personally selected the first bellwether cases in 2026; expert (Daubert) fights are the next gate, and trials are likely in 2027. A separate medical-monitoring class was proposed for users not yet diagnosed. Read the hair relaxer guide.

Roundup (MDL 2741). Plaintiffs allege the glyphosate weedkiller caused non-Hodgkin lymphoma. This is the most legally consequential tort of 2026, and it just went through a major shift: on June 25, 2026, the U.S. Supreme Court ruled 7–2 for Monsanto in Monsanto Co. v. Durnell, holding that federal pesticide law (FIFRA) preempts state-law failure-to-warn claims once the EPA has made a safety determination — the legal theory behind most Roundup lawsuits. Bayer has since asked the federal MDL judge to dismiss the roughly 3,900 pending federal cases, though plaintiffs’ attorneys note that design-defect and negligence claims survive the ruling. Separately, Bayer’s proposed $7.25 billion class settlement — covering an estimated 65,000 claims with individual payouts in the $6,000–$165,000+ range — was filed in Missouri state court and received preliminary approval there in March 2026, but objectors removed the case to the existing federal Roundup MDL in California, now before Judge Vince Chhabria. The court has since pushed the final fairness hearing back twice — first from July 9 to August 19, and, as of a mid-August order, again to September 14, 2026 — while it works through disputes over the validity of certain opt-out requests; the opt-out deadline has correspondingly moved to August 21, 2026. Registration and claim submission are not yet open. Check the settlement’s official case website or the docket for the latest before assuming either outcome. Read the Roundup guide.

Paraquat (MDL 3004). Agricultural workers and others exposed to the herbicide paraquat allege it caused Parkinson’s disease. The parties signed a settlement framework in 2025, and a court-approved settlement fund was set up in March 2026, with the MDL largely paused while the deal is finalized and plaintiffs decide whether to opt out. Cases are still being accepted, and Syngenta announced in 2026 that it will stop producing paraquat. Terms are confidential. Read the Paraquat guide.

AFFF firefighting foam (MDL 2873). Firefighters, military service members, airport workers, and people with contaminated water allege the PFAS “forever chemicals” in firefighting foam caused kidney cancer, testicular cancer, and other illnesses. About 15,000 personal-injury cases are pending before Judge Gergel in South Carolina. The judge paused formal intake in late 2025, but cases continue to be filed and can still join. Read this carefully: the multibillion-dollar 3M and DuPont AFFF settlements you may have seen are water-utility deals to clean up public water systems — not one dollar of that money goes to individual cancer patients, who must pursue separate personal-injury claims. No personal-injury settlement exists yet. Read the AFFF guide.

Environmental & occupational torts

Mesothelioma & asbestos. The oldest mass tort of all is still very much open. More than 60 asbestos bankruptcy trusts hold an estimated $30 billion-plus set aside to compensate people diagnosed with mesothelioma, lung cancer, and asbestosis from exposure to asbestos in workplaces, products, and buildings. Trust claims and traditional lawsuits can both apply. Because mesothelioma has a decades-long latency, many people are still within their filing window. Mesothelioma lawsuits · asbestos exposure claims.

Technology & abuse torts

These cases involve minors and sexual abuse. They are described here factually and without graphic detail; if you or your child has been affected, a confidential case review with an attorney is the right next step.

Social-media harm (MDL 3047). Parents, adolescents, school districts, and state attorneys general allege that platforms including Instagram, TikTok, Snapchat, and YouTube were designed to be addictive and contributed to serious adolescent mental-health harms. Roughly 2,700 cases sit in the federal MDL in California, with thousands more coordinated in California state court. A key legal question is whether Section 230 shields platforms; courts have allowed claims that target the products’ design (rather than user content) to proceed. The litigation is still accepting plaintiffs.

Roblox (MDL 3166). Families allege the gaming platform failed to protect children from predators who used it to make contact and groom minors. This is a newer docket (formed December 2025, about 160 federal cases) before the Chief Judge in the Northern District of California, with parallel state cases and a court-appointed settlement master. Several state attorneys general have reached enforcement settlements with Roblox — but those are government penalties earmarked for child-safety programs, not compensation to individual families, who must file their own civil claims. Still accepting cases.

Uber passenger assault (MDL 3084). Survivors allege Uber drivers sexually assaulted them and that the company failed to screen drivers and protect riders. About 3,600 cases are consolidated before Judge Breyer in California, with parallel state cases (and related Lyft claims). Two early bellwether trials in 2026 both found Uber liable, on theories that include “common carrier” duties and apparent agency. Some cases have settled, but there is no global resolution. Still accepting cases.

Birth & infant torts

NEC baby formula (MDL 3026). Families allege that cow’s-milk-based preterm infant formula (Similac from Abbott and Enfamil from Mead Johnson) caused necrotizing enterocolitis, a devastating intestinal disease, in premature babies fed the products in the NICU — without adequate warning. About 800 cases sit before Chief Judge Pallmeyer in Illinois. Be aware of an honest split: state-court juries have returned very large verdicts (including $60 million, $495 million, and a $70 million award to four mothers in April 2026), but the manufacturers have won the first federal bellwether cases on summary judgment after courts excluded the plaintiffs’ causation experts. The next federal trial — the first to target Enfamil — is set for mid-2026. Still accepting claims, typically for infants born before 37 weeks who were fed the formula and diagnosed with NEC. Read the NEC guide.

Closed or On Hold (Don’t Miss This)

Not every tort you read about is still open. Being honest about that is the whole point of this page.

Camp Lejeune — filing window closed August 10, 2024; new global-settlement deadline of October 30, 2026. The Camp Lejeune Justice Act gave people exposed to contaminated water at the North Carolina base (1953–1987) a two-year window to file administrative claims with the Navy. That window closed on August 10, 2024, and the Navy is no longer accepting new claims. There is one narrow exception: if you filed an administrative claim before the deadline and the Navy then denied it (or failed to respond for six months), you generally have 180 days to file a lawsuit in federal court. For those who already filed, there is real news to watch: in June 2026, the four federal judges overseeing the litigation ordered the Department of Justice and the Plaintiffs’ Leadership Group to reach a global settlement framework by October 30, 2026, with mandatory weekly negotiation sessions — or face leadership restructuring and possible court action against the government’s defense team. The government’s Elective Option settlement program has separately paid out more than $700 million so far, though that remains a small fraction of the roughly 400,000+ administrative claims filed. Read the Camp Lejeune guide.

Tylenol autism (MDL 3043) — federal MDL dismissed, on appeal. The federal judge excluded all of the plaintiffs’ causation experts and granted summary judgment to the defendants, effectively ending the federal litigation over claims that prenatal acetaminophen causes autism or ADHD. Plaintiffs appealed to the Second Circuit, which heard arguments in late 2025; a decision is pending. Some state-court cases continue. This one is best described as unsettled and uphill, not open in the ordinary sense.

Exactech implants — paused by bankruptcy. Lawsuits over prematurely failing Exactech knee, hip, and ankle implants are largely stayed by the company’s Chapter 11 bankruptcy. Any resolution — and the value of claims — now depends on that bankruptcy process rather than on ordinary tort trials.

How Much Are Mass Tort Settlements?

Here is the part the internet gets most wrong. You will see pages confidently quoting an “average payout” for torts that have no settlement at all. Treat those numbers with deep skepticism — if there is no settlement and no string of verdicts, there is no reliable per-person figure, only marketing.

As of August 2026, genuinely documented compensation exists for these torts:

• Talcum powder: a proposed $5.5 billion settlement (July 2026) covering roughly 76,000 ovarian-cancer claims — not yet final, conditioned on 95% participation.
• Roundup: a proposed $7.25 billion class settlement with estimated individual awards roughly in the $6,000–$165,000+ range — pending final approval (hearing now set for Sept 14, 2026, before the federal MDL judge in California), and complicated by the Supreme Court’s June 2026 Durnell ruling.
• Paraquat: a signed settlement framework with a court-approved fund, but the terms and amounts are confidential.
• Zantac: GSK settled roughly 80,000 claims for up to $2.2 billion; Sanofi separately settled about 4,000 more.
• AFFF water-provider deals: billions paid — but to public water systems, not to injured individuals.
• Asbestos trusts: long-established trust payment schedules backed by $30 billion-plus.
• Hernia mesh: Bard’s roughly $1 billion resolution (2024).
• Camp Lejeune: the government’s Elective Option grid, with individual offers commonly reported in the $100,000–$550,000 range depending on injury category, though only a small share of claims have resolved this way so far.

For everything else — hair relaxer, Depo-Provera, Ozempic, Bard PowerPort, Suboxone, Taxotere, Uber, Roblox, social media, NEC — there is no global settlement, which means there is no real average. Where you see a precise dollar figure for those, it is almost certainly an estimate or a projection, not a promise. When settlements do come, they typically depend on injury severity, the strength of your evidence, your state’s law, and how the early bellwether trials shake out. Being straight about this is the difference between a guide that helps you and one that is selling you something.

Medical Liens: The Surprise Nobody Warns You About

Winning a mass tort case does not always mean the full check is yours to keep. If Medicare, Medicaid, or a private insurer (like Blue Cross) paid for treatment related to your injury, they generally have a legal right — a lien — to be reimbursed out of your settlement before you receive the remainder. Your attorney typically negotiates these liens down, but they are a real deduction, alongside attorney’s fees and case expenses, that can meaningfully reduce your net payout. Ask your attorney early how liens will be handled in your specific case, not after the settlement check arrives.

How Long They Take & What They Cost

Timeline. Mass torts are not quick. A typical path runs: cases are filed and consolidated into an MDL, then move through discovery, expert “science day” and Daubert hearings, then a small set of bellwether (test) trials, and only then — if at all — toward a settlement and payout. From filing to money in hand often takes several years, and some of these dockets are years from their first trial. Bellwether outcomes are the main accelerant: a string of plaintiff wins tends to push a defendant toward settlement, while defense wins can stall things.

Cost. Almost all mass tort cases are handled on a contingency-fee basis. You pay nothing up front; the attorney advances the costs (called case expenses — things like expert witnesses, court filings, and medical-record retrieval) and is paid a percentage of any recovery — commonly in the 33–40% range — only if you actually recover, with case expenses typically deducted alongside that percentage. Initial case reviews are free. One notable exception: Camp Lejeune claims are subject to statutory fee caps (generally 20% for administratively settled claims and 25% for cases resolved through litigation). Always get the fee structure in writing before you sign.

2026 Bellwether Results & What’s Next

Bellwether verdicts are the scoreboard that moves settlements. The 2026 results so far have been a genuinely mixed bag — which is part of why so few torts have settled, and why the ones that just did (talc, and possibly Roundup) are such a big deal.

Verdicts so far in 2026: In the social-media litigation, a Los Angeles jury hit Meta and YouTube with a $6 million verdict in late March (the companies are appealing), and the first federal school-district bellwether settled for a reported figure before its June trial. In the Uber litigation, the first federal bellwether returned an $8.5 million verdict in February, followed by a much smaller $5,000 verdict in a second case in April — both finding Uber liable. The first Bard PowerPort bellwether ended in a defense verdict in May. In talc, state-court juries returned enormous awards (including $1.5 billion in Baltimore in December 2025 and $966 million in Los Angeles, where the $950 million punitive portion was later vacated and the $16 million compensatory award left standing), plus a $32 million Los Angeles mesothelioma verdict in June 2026 — all against the backdrop of J&J’s new $5.5 billion settlement offer. NEC produced a $70 million state verdict in April — even as the manufacturers kept winning federal bellwethers.

What’s next: The single biggest legal event of 2026 already happened — the U.S. Supreme Court ruled 7–2 for Monsanto in Monsanto v. Durnell (No. 24-1068) on June 25, 2026, holding that federal pesticide law preempts state failure-to-warn claims. That decision is now colliding directly with the Roundup class settlement’s fairness hearing, which a Missouri court order pushed back a second time — first from July 9 to August 19, then to September 14, 2026 — while the parties sort out disputes over opt-out requests. Also ahead: whether Johnson & Johnson’s 76,000-claim talc settlement reaches the 95% participation threshold it needs to become final (plaintiffs’ firms are actively collecting participation commitments now), the Camp Lejeune global-settlement deadline of October 30, 2026, the first federal talc bellwether later in 2026, and the next Uber bellwethers in September.

For court counts and docket numbers, the most authoritative source is the JPML’s pending-MDL reports; the Supreme Court docket for Monsanto v. Durnell tracks that ruling in real time. Wire services such as Reuters are reliable for verdicts and settlement news.

Frequently Asked Questions

How do I know if I qualify for a mass tort lawsuit?

You generally need three things: documented use of or exposure to the product, a diagnosis of one of the injuries that the specific litigation covers, and a filing within your state’s deadline. A free case review can tell you whether your facts fit a particular tort.

Which mass torts are still accepting new plaintiffs in 2026?

Most active torts are — including talc, hair relaxer, Depo-Provera, AFFF, Bard PowerPort, Suboxone, Ozempic, Zantac, Taxotere, Uber, Roblox, social media, NEC, Roundup, and Paraquat. Camp Lejeune is the major exception: its filing window closed on August 10, 2024.

Is a mass tort the same as a class action?

No. In a mass tort (usually an MDL), each person keeps an individual case and an individual payout based on their own injury. A class action produces one shared outcome divided among the class. Roundup is the notable 2026 case being resolved as a class settlement rather than a typical MDL payout.

How much money will I get from a mass tort settlement?

There is no honest one-size answer, and most torts have no settlement at all yet — meaning no real per-person figure exists. Where settlements do exist, amounts depend on injury severity, evidence, and your state’s law. Be skeptical of any site quoting an exact “average” payout for a tort that hasn’t settled.

Is it too late to file a Camp Lejeune claim?

For new claims, yes — the deadline was August 10, 2024, and the Navy is no longer accepting new claims. The one exception: if you filed a claim before that date and it was later denied, you generally have 180 days from the denial to file a lawsuit in federal court. For everyone who already filed, watch the court’s October 30, 2026 deadline for a global settlement framework.

Can I join a mass tort lawsuit if my insurance already covered my medical bills?

Yes. Having insurance pay your medical bills does not disqualify you from a claim. It does mean the insurer (or Medicare/Medicaid) may have a lien on your eventual settlement to be reimbursed for what it paid — see the medical liens section above.

What happens if the plaintiff dies before the mass tort settles?

The case does not simply disappear. In most states, it can continue as a “survival action” brought by the estate or a wrongful-death claim brought by surviving family members, depending on state law and the circumstances.

Are mass tort settlement payouts taxable?

Generally, compensation for physical injury or physical sickness is not taxable by the IRS. Punitive damages, and any portion attributed to interest, generally are taxable. Rules vary by case and state, so this is worth confirming with a tax professional for your specific settlement.

Can I switch lawyers if my mass tort case is moving too slowly?

Generally yes, though it’s worth understanding the fee arrangement first — your original attorney may be entitled to a portion of the fee for work already done, and switching mid-case can sometimes cause delays of its own. A consultation with a new firm can clarify the tradeoffs before you decide.

How much does a lawyer take from a mass tort settlement?

Typically 33–40% of the recovery under a contingency agreement, plus separately deducted case expenses (expert witnesses, filing fees, medical-record costs). Camp Lejeune is a notable exception, with statutory fee caps of 20% (administrative settlements) or 25% (litigated cases).

How long does a mass tort lawsuit take?

Often several years. Cases move through consolidation, discovery, expert hearings, and bellwether trials before settlement or payout. The pace depends heavily on how the early test trials go.

Does it cost anything to join a mass tort lawsuit?

Almost always no money up front. These cases run on contingency — the attorney is paid a percentage (commonly 33–40% plus costs) only if you recover. Camp Lejeune claims are an exception, with statutory fee caps of 20% or 25%.

What is a bellwether trial?

A bellwether is a representative test case tried early in an MDL so both sides can see how juries react to the evidence. The verdicts don’t bind the other cases, but they heavily influence settlement value and strategy.

Can I be part of more than one lawsuit?

Potentially, if you have distinct injuries from distinct products — for example, separate exposures to two different drugs or devices. Each claim has to stand on its own use, diagnosis, and deadline. An attorney can tell you whether your situation supports more than one claim.

What documents do I need to file a claim?

Typically proof of use or exposure (prescription records, implant cards, employment or service records, receipts, or account records), medical records confirming your diagnosis and its date, and anything that connects the product to your injury. Complete records are the strongest predictor of whether a claim advances.

What is a “common benefit fee” in a mass tort settlement?

In many federal MDLs, the judge orders that a percentage of every plaintiff’s recovery — commonly in the single digits to around 10% — be set aside to compensate the lead/leadership attorneys who handle the shared work (discovery, expert development, bellwether trials) on behalf of everyone in the litigation. This is separate from, and in addition to, your own attorney’s individual contingency fee, so it’s worth asking your lawyer how it applies in your case.

Can I qualify for more than one mass tort at the same time?

Yes, if you have distinct injuries tied to distinct products or exposures — for example, someone exposed to AFFF firefighting foam who separately took a drug linked to a different injury could potentially pursue two separate claims in two different MDLs. Each claim is evaluated independently on its own use, diagnosis, and deadline.